Zoetis Gets Wall Street's Top Bet as the OA Pain Market Enters Its Next Phase

Citi named Zoetis its top pick in animal health this week, setting a $145 price target and opening a 90-day catalyst watch on the company's embattled mAb franchise. The timing isn't random. Zoetis is about to launch two long-acting osteoarthritis drugs in the EU and Canada while a stem cell startup just reported positive feline OA data on the same day. The pet OA market, valued at $2.3 billion in 2024, is projected to hit $13 billion by 2033. The race to own it is accelerating.

What Happened

On April 15, Citi initiated coverage on Zoetis (NYSE: ZTS) with a Buy rating and $145 price target, naming it the firm's top pick across the animal health group. The core thesis: osteoarthritis affects roughly 40% of dogs and cats, and Zoetis has the deepest pipeline to capture that market across multiple treatment modalities and dosing intervals.

Citi opened what it called an "upside 90-day catalyst watch," betting that Solensia (the monthly feline OA injection) will return to growth in fiscal 2026 after a difficult stretch. U.S. mAb product revenue declined 12% in full-year 2025, with Librela (dogs) down 16% and Solensia (cats) down 7%. The Q4 2025 numbers were worse: the U.S. OA pain franchise fell 25% in the quarter, with Librela posting $36 million in revenue (down 32%) and Solensia at $17 million (down 7%).

Management attributed the decline to soft clinic visit volumes and economic pressure on Gen Z and millennial pet owners causing "greater price sensitivity for routine care." Zoetis expects those headwinds to persist into 2026.

What Citi sees beyond the current softness: two next-generation OA drugs approaching commercial launch. Lenivia, a three-month dosing injection for dogs, received a positive opinion from the EU's Committee for Veterinary Medicinal Products and is expected to launch commercially in the EU and Canada this year. Portela, the first three-month mAb therapy for feline OA, has already been approved in both markets. Together, they give Zoetis a four-product OA portfolio spanning dogs and cats at both monthly and quarterly dosing intervals.

Meanwhile, the company's 2026 guidance of $7.00 to $7.10 in adjusted EPS topped the Wall Street consensus of $6.80, and the pending $160 million acquisition of Neogen's GeneSeek genomics business (expected to close in H2 2026) adds precision diagnostics to the mix.

Why It Matters

1. The OA pain market is entering a multi-modality era. Zoetis built the category with Librela and Solensia, but the next chapter isn't a monopoly play. On the same day Citi published its note, Gallant reported positive pilot data for its IV stem cell therapy targeting feline OA and received FDA eligibility for the expanded conditional approval pathway. OA affects up to 90% of cats over 12 years old. Gallant's approach (regenerative, potentially one-time) competes directly with Zoetis's model (symptom management, recurring injections). Add the existing $3 billion-plus OTC supplement market (glucosamine, CBD, joint chews), and clinic operators now face a genuinely complex formulary decision for the first time in this category.

2. Three-month dosing changes clinic economics. Lenivia and Portela shift the visit cadence from monthly to quarterly for OA patients. For clinics generating meaningful revenue from monthly injection appointments, this math cuts both ways. Fewer visits per patient, but potentially higher per-visit value and better compliance rates. Clinic operators should be modeling what this transition looks like on their P&L before these products hit their markets. The question is whether quarterly dosing expands the total addressable patient pool by making treatment more accessible to price-sensitive owners, or whether it simply compresses existing revenue into fewer touchpoints.

3. Zoetis is building a three-layer moat. The Citi note arrives during a period of unusual strategic density for Zoetis. Layer one: next-gen OA therapeutics (Lenivia and Portela). Layer two: precision animal health via the Neogen/GeneSeek genomics acquisition, which adds labs in five countries and customers across 120-plus markets. Layer three: the Solensia and Librela recovery play, where Citi is betting that current demand softness is cyclical, not structural. If all three execute, Zoetis will control the OA category end-to-end while building data infrastructure that competitors would need years to replicate.

4. The clinic visit headwind matters for everyone, not just Zoetis. Management's comments about Gen Z and millennial pet owners pulling back on therapeutic visits is a macro signal. If Zoetis, with the strongest brand in animal health, is feeling visit-volume pressure, smaller players and independent clinics are feeling it more. Watch Tractor Supply's Q1 earnings on April 21 for the next data point on pet consumer spending.

What to Watch

Solensia growth inflection: Citi's 90-day window puts us at mid-July. If Solensia doesn't show sequential improvement by Zoetis's Q1 2026 earnings call on May 7, the catalyst thesis weakens.

Lenivia and Portela launch cadence: EU and Canadian commercial launches are expected in 2026, but "expected" and "generating revenue" are different milestones. Watch for distributor agreements and initial order data.

Gallant's regulatory path: The FDA expanded conditional approval pathway is faster than traditional approval, but Gallant's therapy is still investigational. The timeline from here to even conditional market availability is likely 18-plus months. Still, the competitive signal is real: Zoetis isn't the only company with a viable approach to feline OA.

Zoetis Q1 2026 earnings (May 7): The first post-guidance data point. Key metrics: U.S. companion animal growth, mAb franchise trajectory, and any commentary on Lenivia/Portela launch timelines. Paired with Tractor Supply (April 21) and Freshpet (May 6), this earnings cluster will define the Q1 2026 narrative for the pet economy.

Source: Citi initiates Zoetis coverage via 24/7 Wall St. · Gallant pilot data via BioSpace · Zoetis Q4 2025 earnings via Morningstar